Jason explores the growing research around GLP-1 medications and their potential role in addiction treatment, including how these medications may impact cravings, dopamine signaling, reward pathways, relapse prevention, and the connection between metabolic health and substance use disorders
Being declined by one processor doesn't mean universal rejection, different processors have different risk tolerances
The rise of ozempic face: analyzing trends and treatment challenges associated with rapid facial weight loss induced by GLP-1 agonists
Verghese PB, Castellano JM, Garai K, Wang Y, Jiang H, Shah A, et al
Acute pancreatitis has been reported in clinical trials of tirzepatide, though the incidence is low, approximately 0.2 percent
Changing your lifestyle is challenging, but it is fundamental not only for weight loss but also for improving overall health (weight loss does not equal better health), she noted